CONTENTS:
Figure S1 10 Controls for ATPS in w/o droplets containing an ATPS composition 10% dextran, 7% PEG and19.8% dextran, 2.8% PEG after incubation at 37 °C for 2 h. 
A2PS and A3PS compositions.
Three different ATPS compositions were encapsulated in w/o emulsions, including 19.8% (w/w) dextran 10 kDa, 2.8% (w/w) PEG 8 kDa; 10% (w/w) dextran 10 kDa, 7% (w/w) PEG 8 kDa; 18.5%(w/w) dextran 10 kDa, 5.5% (w/w) PEG 8 kDa. The ATPS compositions used for the expression of mYPet in w/o emulsion droplets were 20% (w/w) dextran, 14% (w/w) PEG and 39.6% (w/w) dextran and 5.6% (w/w) PEG before two-fold dilution with T/T components. The PEG was labeled using Amicon Ultra 0.5 mL centrifugal filters with a cut off of 10 kDa. Each solution was made by directly dissolving the components in 5 mL deionized H 2 O with stirring with a magnetic stir plate. The A3PS composition was 19.8% (w/w) dextran 10 kDa, 2.8% (w/w) PEG 8 kDa, 5%(w/w) Ficoll 400 kDa. To produce the A3PS, 1 mL of 30% (w/w) Ficoll 400 kDa was first prepared and then added to a previously made ATPS of 19.8% (w/w) dextran 10 kDa, 2.8% (w/w) PEG 8 kDa with a positive displacement pipet (Gilson).
Encapsulation of ATPS in vesicle.
Vesicles were made with 1-palmitoyl-2-oleoyl-snglycero-3-phosphocholine (POPC). Lipid stocks were made by dissolving 1 g POPC in 25 mL chloroform to obtain a 40 mg/mL solution. With a glass pipette an aliquot of the lipid stock was transferred to a round bottom flask. The organic solvent was then evaporated with a Buchi Rotovapor R-210 for 30 min. This procedure resulted in the formation of a thin lipid film. Next, 1 mL of ATPS was added to hydrate the lipid, giving a final concentration of 70 mM POPC. Vesicles were then formed by dispersing the lipid by vortexing at 3200 rpm. Transcription-translation inside of w/o emulsions containing aqueous multiphase systems. 25 µL of the PURExpress 1 in vitro protein synthesis kit (New England BioLabs) containing 250 ng plasmid template encoding mYPet (RL001A 2 ) was added to 25 µL of previously made ATPS with gentle mixing in a microcentrifuge tube. The resulting final volume of 50 µL was added to 0.95 mL of the oil phase plus surfactants. The sample was incubated at 37 °C for at least 6 h. Images were acquired every 2 h by confocal microscopy.
Encapsulation of ATPS and
Confocal microscopy. Aqueous phases were visualized by including fluorescently labeled polymers during ATPS and A3PS formation. For the dextran enriched phase, either Alexa 647 conjugated with dextran 10 kDa or dextran 40 kDa was used at a final concentration of 4 µg/µL for ATPS and 0.8 µg/µL for A3PS. The PEG enriched phase was labeled with Alexa 488 conjugated with PEG 20 kDa or PEG 5 kDa was used at a final concentration of 7.2 µg/µL for ATPS and 3.6 µg/µL for A3PS. 12 µg/µL Ficoll labeled with tethramethylrhodamine isothiocyanate enriched was used to label the Ficoll enriched phase.
